Veracyte study shows Decipher test predicts abiraterone benefit in very high-risk prostate cancer
VCYT•Veracyte will present six genomic test studies at the ESMO Congress in Madrid on October 23-27, 2026; Decipher Prostate findings will provide first evidence predicting benefit from adding abiraterone to androgen deprivation therapy in clinically very high-risk, nonmetastatic disease.
1. Congress presentations
Veracyte will present six genomic test studies at the ESMO Congress in Madrid, October 23-27, 2026. Decipher Prostate findings will provide first evidence predicting benefit from adding abiraterone to androgen deprivation therapy in clinically very high-risk, nonmetastatic prostate cancer.
2. Prosigna analysis
An October 25 presentation will examine the economics of Prosigna-guided chemotherapy decisions using two-year results from the Phase III OPTIMA breast cancer trial.
